Welcome to LookChem.com Sign In|Join Free
  • or
2'-Deoxycytidine monohydrate is a deoxyribonucleotide that plays a crucial role in the synthesis of DNA. It has been demonstrated to inhibit the kinase activity of IL-2 receptor and Toll-like receptor, which are proteins involved in regulating the immune response. Additionally, 2'-Deoxycytidine inhibits DNA polymerase activity and thermal expansion, making it a potential candidate for use as an anticancer drug.

951-77-9

Post Buying Request

951-77-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

951-77-9 Usage

Uses

Used in Pharmaceutical Industry:
2'-Deoxycytidine monohydrate is used as an anticancer agent for its ability to inhibit the kinase activity of IL-2 receptor and Toll-like receptor, as well as DNA polymerase activity and thermal expansion. This makes it a promising candidate for the development of cancer treatments.
Used in DNA Synthesis:
2'-Deoxycytidine monohydrate is used as a deoxynucleoside, which, after phosphorylation to dCTP, is utilized in the synthesis of DNA through various DNA polymerases or reverse transcriptases. This process is essential for the replication and repair of genetic material in cells.
Used in Enzymatic Conversion:
2'-Deoxycytidine monohydrate serves as a substrate for deoxycytidine deaminase (EC 3.5.4.14), an enzyme that converts it into 2'-deoxyuridine. This conversion is an important step in the metabolic pathway of nucleosides and nucleotides.
Used in Nucleotide Phosphorylation:
2'-Deoxycytidine monohydrate is phosphorylated to the nucleotide dCMP by the enzyme deoxycytidine kinase (DCK). This phosphorylation is a key process in the activation of deoxynucleosides, allowing them to be incorporated into DNA.

Biological Activity

2-deoxycytidine is a cytidine analog [1].2-deoxycytidine prevents dna methylation by incorporating itself into newly synthesizing dna strand. 2-deoxycytidine also binds to dna methyltransferase irreversibly and hinders its activity. thus, 2-deoxycytidine was approved as the most efective demethylating agent for the treatment of cancer [1].2-deoxycytidine at clinically achievable and nontoxic concentrations (≥ 100 μmol/l) protected normal bone marrow progenitor cells against the inhibitory effects of co-administered, high concentrations of 3’-azido-3’-deoxythymidine (azt) (≥ 10 μmol/l). in normal bone marrow mononuclear cells (bmmc), 2-deoxycytidine also significantly corrected azt-mediated depletion of intracellular thymidine triphosphate and 2-deoxycytidine triphosphate levels. furthermore, 2-deoxycytidine reduced the intracellular accumulation of azt triphosphate and its dna incorporation in bmmc [2].in a rat model of myocardial infarction induced by ligating left anterior descending coronary artery, human umbilical cord mesenchymal stem cells treated with 2-deoxycytidine (5, 10, 20 and 40 μm) before transplantation to the left ventricular wall immediately after ligation significantly improved the cardiac systolic and diastolic functions, and pumping ability. fibrotic area and left ventricular wall thickness were also significantly improved [1].[1]. ali s r, ahmad w, naeem n, et al. small molecule 2'-deoxycytidine differentiates human umbilical cord-derived mscs into cardiac progenitors in vitro and their in vivo xeno-transplantation improves cardiac function. molecular and cellular biochemistry, 2020, 470(1-2): 99-113.[2]. bhalla k, birkhofer m, li g r, et al. 2'-deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. blood, 1989, 74(6): 1923-1928.

Biochem/physiol Actions

2′-Deoxycytidine (deoxyC) forms dCTP upon phosphorylation which is used to synthesis DNA via various DNA polymerases or reverse transcriptases. DeoxyC is the substrate for deoxycytidine deaminase (EC 3.5.4.14) which converts it into 2′-deoxyuridine. DeoxyC is phosphorylated to the nucleotide dCMP by the enzyme deoxycytidine kinase (DCK). DeoxyC serves as a potential head and neck cancer marker.

Safety Profile

Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

Check Digit Verification of cas no

The CAS Registry Mumber 951-77-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,5 and 1 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 951-77:
(5*9)+(4*5)+(3*1)+(2*7)+(1*7)=89
89 % 10 = 9
So 951-77-9 is a valid CAS Registry Number.

951-77-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (D3583)  2'-Deoxycytidine  >98.0%(HPLC)(T)

  • 951-77-9

  • 1g

  • 240.00CNY

  • Detail
  • TCI America

  • (D3583)  2'-Deoxycytidine  >98.0%(HPLC)(T)

  • 951-77-9

  • 5g

  • 890.00CNY

  • Detail

951-77-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2'-deoxycytidine

1.2 Other means of identification

Product number -
Other names 2'-Deoxycytidine monohydrate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:951-77-9 SDS

951-77-9Synthetic route

4-N-picolyl-2'-deoxycytidine
78983-36-5

4-N-picolyl-2'-deoxycytidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia In water at 20℃; for 0.5h;100%
2'-deoxycytidine monohydrochloride
3992-42-5

2'-deoxycytidine monohydrochloride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With Amberlite A-26 (OH- form) In water for 0.5h; Ambient temperature;99%
Multi-step reaction with 4 steps
1: pyridine
2: pyridine / 20 °C
3: 237 mg / water / methanol / 0.5 h
4: acetic acid / dioxane; H2O / 0.67 h / 20 °C / UV-irradiation
View Scheme
Multi-step reaction with 4 steps
1: pyridine
2: pyridine / 20 °C
3: 325 mg / water / methanol / 0.5 h
4: acetic acid / dioxane; H2O / 0.33 h / 20 °C / UV-irradiation
View Scheme
With triethylamine In methanol pH=7;
4-O-(2,4,6-Trimethylphenyl)-2'-deoxyuridine
130197-82-9

4-O-(2,4,6-Trimethylphenyl)-2'-deoxyuridine

A

2'-deoxyuridine
951-78-0

2'-deoxyuridine

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonium hydroxide at 65℃; for 2h;A n/a
B 98%
4-methylamino-1-(β-D-2-deoxyribofuranosyl)pyrimidin-2(1H)-one
22882-02-6

4-methylamino-1-(β-D-2-deoxyribofuranosyl)pyrimidin-2(1H)-one

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With manganese(IV) oxide; C17H20N4O9P(1-)*Na(1+); oxygen In water; acetonitrile at 20℃; under 760.051 Torr; for 7h; Irradiation; chemoselective reaction;95%
3',5'-di-O-acetyl-2'-deoxycytidine
65919-98-4

3',5'-di-O-acetyl-2'-deoxycytidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia at 25℃;93%
With ammonia In methanol at 25℃; for 24h; Yield given;
N4-5'-O-di(triphenylmethyl)-2'-deoxycytidine

N4-5'-O-di(triphenylmethyl)-2'-deoxycytidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonium cerium(IV) nitrate; silica gel In dichloromethane at 25℃; for 2h; detritylation;90%
C23H30BN3O8

C23H30BN3O8

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With dihydrogen peroxide In aq. phosphate buffer; dimethyl sulfoxide at 20℃; for 0.333333h; pH=7.2;88%
6-(2-Deoxy-β-D-ribosyl)tetrazolo<1,5-c>pyrimidine-5(6H)-one
108584-99-2

6-(2-Deoxy-β-D-ribosyl)tetrazolo<1,5-c>pyrimidine-5(6H)-one

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In methanol for 50h;86%
2'-deoxy-4-N-acetylcytidine
380887-00-3

2'-deoxy-4-N-acetylcytidine

ammonia
7664-41-7

ammonia

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
In methanol84.6%
N4-benzoyl-2'-deoxycytidine
4836-13-9

N4-benzoyl-2'-deoxycytidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ethylenediamine at 40℃; for 20h;67%
With ethylenediamine; phenol at 40℃; for 20h; debenzoylation;67%
With sodium hydroxide In methanol; water for 0.0333333h; microwave irradiation;
5-Iodo-2'-deoxycytidine
611-53-0

5-Iodo-2'-deoxycytidine

diphenyldisulfane
882-33-7

diphenyldisulfane

A

5-phenylsulfanyl-2'-deoxycytidine

5-phenylsulfanyl-2'-deoxycytidine

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With [2,2]bipyridinyl; copper In N,N-dimethyl-formamide at 110℃; for 6h; Inert atmosphere; Sealed tube;A 58%
B n/a
2-deoxy–α-D-ribose 1-phosphate
17039-17-7

2-deoxy–α-D-ribose 1-phosphate

Cytosine
71-30-7

Cytosine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With purine nucleoside phosphorylase at 50℃; for 20h; pH=8; aq. buffer; Enzymatic reaction;57.5%

A

α-2'-deoxycytidine
4449-40-5

α-2'-deoxycytidine

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia In methanolA 54%
B 46%
1-(3,5-O-dibenzoyl-2-deoxy-β-D-erythro-pentofuranosyl)-4-methoxy-2-pyrimidone
303041-54-5

1-(3,5-O-dibenzoyl-2-deoxy-β-D-erythro-pentofuranosyl)-4-methoxy-2-pyrimidone

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia In methanol at 100℃; Substitution; deacylation;50%
Cytosine
71-30-7

Cytosine

thymidine
50-89-5

thymidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With nucleoside deoxyribosyltransferase-II; sodium citrate at 40℃; for 20h; pH=6.4; Enzymatic reaction;49.8%
With sodium hydroxide; 1-(3-sulfonatopropyl)piperidine In water at 40℃; Enzymatic reaction;
5-(chloromercuri)-2'-deoxycytidine
65523-09-3

5-(chloromercuri)-2'-deoxycytidine

N,N'-Bis(trifluoroacetyl)cystamine
118042-46-9

N,N'-Bis(trifluoroacetyl)cystamine

A

5-<3-(Trifluoroacetamido)-1-thiapropyl>-2'-deoxycytidine
135638-74-3

5-<3-(Trifluoroacetamido)-1-thiapropyl>-2'-deoxycytidine

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With lithium tetrachloropalladate(II) In methanol Ambient temperature;A 5%
B n/a
N4-acetyl-O3',O5'-bis-(4-chloro-benzoyl)-2'-deoxy-cytidine
101320-23-4

N4-acetyl-O3',O5'-bis-(4-chloro-benzoyl)-2'-deoxy-cytidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia
3',5'-di-O-benzoyl-2'-deoxycytidine
20963-97-7

3',5'-di-O-benzoyl-2'-deoxycytidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonium hydroxide
C53H73N21O37P6

C53H73N21O37P6

A

Phosphoric acid (2R,3S,5R)-5-(2-amino-6-hydroxy-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester (S)-2,3-dihydroxy-1-(2-hydroxy-ethyl)-propyl ester
104779-62-6, 104870-73-7

Phosphoric acid (2R,3S,5R)-5-(2-amino-6-hydroxy-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester (S)-2,3-dihydroxy-1-(2-hydroxy-ethyl)-propyl ester

B

2'-deoxyguanosine
961-07-9

2'-deoxyguanosine

C

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
1.) P1 nuclease, NaOAc (pH 5.5), ZnCl2, 37 deg C, 1.5 h, 2.) alkaline phosphatase, Tris-HCl (pH 7.5), 37 deg C, 30 min; Yield given. Multistep reaction;
C53H73N21O36(18)OP6

C53H73N21O36(18)OP6

A

Cytosine
71-30-7

Cytosine

B

C15H24N5O9(18)OP

C15H24N5O9(18)OP

C

2'-deoxyguanosine
961-07-9

2'-deoxyguanosine

D

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
1.) P1 nuclease, NaOAc (pH 5.5), ZnCl2, 37 deg C, 1.5 h, 2.) alkaline phosphatase, Tris-HCl (pH 7.5), 37 deg C, 30 min; Yield given. Multistep reaction;
C53H71(2)H2N21O37P6

C53H71(2)H2N21O37P6

A

C15H22(2)H2N5O10P

C15H22(2)H2N5O10P

B

2'-deoxyguanosine
961-07-9

2'-deoxyguanosine

C

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
1.) P1 nuclease, NaOAc (pH 5.5), ZnCl2, 37 deg C, 1.5 h, 2.) alkaline phosphatase, Tris-HCl (pH 7.5), 37 deg C, 30 min; Multistep reaction;
2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

2'-deoxycytidine deprotonated radical cation

2'-deoxycytidine deprotonated radical cation

A

2'-deoxyguanosine deprotonated radical cation

2'-deoxyguanosine deprotonated radical cation

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
at 20℃; Rate constant; pH = 7.0;
N-Fmoc-dC
87424-19-9

N-Fmoc-dC

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonium hydroxide In pyridine at 20℃; for 0.5h;
N4-isobutyryll-2'-deoxycytidine
110522-75-3

N4-isobutyryll-2'-deoxycytidine

A

4-methylamino-1-(β-D-2-deoxyribofuranosyl)pyrimidin-2(1H)-one
22882-02-6

4-methylamino-1-(β-D-2-deoxyribofuranosyl)pyrimidin-2(1H)-one

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia; methylamine In water at 65℃; for 1h; Product distribution; deprotection reagent;A 0.7 % Chromat.
B n/a
1-(2-Deoxy-3,5-di-O-acetyl-β-D-ribosyl)-4-chloropyrimidin-2(1H)-one
108584-97-0

1-(2-Deoxy-3,5-di-O-acetyl-β-D-ribosyl)-4-chloropyrimidin-2(1H)-one

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With ammonia at 50℃; for 8h; Product distribution;
C33H46N11O22P3

C33H46N11O22P3

A

2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

B

Phosphoric acid (2R,3S,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-yl ester (2R,3S)-2,3,5-trihydroxy-pentyl ester
139924-17-7

Phosphoric acid (2R,3S,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-yl ester (2R,3S)-2,3,5-trihydroxy-pentyl ester

C

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With sodium tetrahydroborate 2) snake venom phosphodiesterase, A. P.; Yield given. Multistep reaction;
C33H46N11O22P3

C33H46N11O22P3

A

2'-Deoxyguanosine
961-07-9

2'-Deoxyguanosine

B

Phosphoric acid (2R,3S,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-yl ester (2R,3S)-2,3,5-trihydroxy-pentyl ester
139924-17-7

Phosphoric acid (2R,3S,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-yl ester (2R,3S)-2,3,5-trihydroxy-pentyl ester

C

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Conditions
ConditionsYield
With sodium tetrahydroborate 2) snake venom phosphodiesterase, A. P.; Yield given. Multistep reaction;
C39H49N9O25P3(3-)

C39H49N9O25P3(3-)

A

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

B

thymidine
50-89-5

thymidine

Conditions
ConditionsYield
With alkaline phosphatase; snake venom phosphodiesterase enzymatic hydrolysis of various tetranucleosides;
C53H75N13O32P4
115173-87-0

C53H75N13O32P4

A

putrescinylthymidine
90289-35-3

putrescinylthymidine

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

C

thymidine
50-89-5

thymidine

Conditions
ConditionsYield
nuclease S1; VPDase (with APase) Product distribution; multistep reaction;
C53H75N13O32P4

C53H75N13O32P4

A

putrescinylthymidine
90289-35-3

putrescinylthymidine

B

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

C

thymidine
50-89-5

thymidine

Conditions
ConditionsYield
nuclease S1; VPDase (with APase) Product distribution; multistep reaction;
1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane
69304-37-6

1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

2'-deoxy-3',5'-di-O-1,1,3,3-(tetraisopropyldisiloxane-1,3-diyl)cytidine
102434-71-9

2'-deoxy-3',5'-di-O-1,1,3,3-(tetraisopropyldisiloxane-1,3-diyl)cytidine

Conditions
ConditionsYield
With pyridine at 20℃;99.9%
With pyridine Ambient temperature;97%
With pyridine at 20℃; for 4h; Inert atmosphere;55%
2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

2'-deoxyuridine
951-78-0

2'-deoxyuridine

Conditions
ConditionsYield
With cytidine deaminase enzyme In aq. phosphate buffer at 37℃; for 0.0833333h; pH=7; Enzymatic reaction;99%
With acetic acid; sodium nitrite
With sodium hydroxide at 90.1℃; Rate constant; Mechanism; various reagent concentration, decomposition to nonchromophoric products;
tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

benzoic acid anhydride
93-97-0

benzoic acid anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-benzoyl-O3',O5'-bis(tert-butyldimethylsilyl)-2'-deoxycytidine
51549-38-3

N4-benzoyl-O3',O5'-bis(tert-butyldimethylsilyl)-2'-deoxycytidine

Conditions
ConditionsYield
Stage #1: tert-butyldimethylsilyl chloride; 2'-Deoxycytidine With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 4h;
Stage #2: benzoic acid anhydride In N,N-dimethyl-formamide at 160℃; for 0.25h; microwave irradiation; Further stages.;
99%
acetic anhydride
108-24-7

acetic anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-acetyl-2'-deoxycytidine
32909-05-0

N4-acetyl-2'-deoxycytidine

Conditions
ConditionsYield
In N,N-dimethyl-formamide98%
In methanol for 3h; Heating;
benzoic acid anhydride
93-97-0

benzoic acid anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-benzoyl-1-(3',5'-di-O-benzoyl-2'-deoxy-β-D-ribofuranosyl)-cytosine
31501-22-1

N4-benzoyl-1-(3',5'-di-O-benzoyl-2'-deoxy-β-D-ribofuranosyl)-cytosine

Conditions
ConditionsYield
With dmap; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 0.0177778h; microwave irradiation;98%
o-nitroiodobenzene
609-73-4

o-nitroiodobenzene

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N6-2-nitrobenzen-1-yl-2'-deoxycytidine

N6-2-nitrobenzen-1-yl-2'-deoxycytidine

Conditions
ConditionsYield
With tetraethylammonium fluoride; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; tris(dibenzylideneacetone)dipalladium (0) In dimethyl sulfoxide at 20℃;98%
propionic acid anhydride
123-62-6

propionic acid anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-propionyl-2'-deoxycytydine
199593-07-2

N4-propionyl-2'-deoxycytydine

Conditions
ConditionsYield
In N,N-dimethyl-formamide96%
ammonium hydroxide
1336-21-6

ammonium hydroxide

benzoyl chloride
98-88-4

benzoyl chloride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-benzoyl-2'-deoxycytidine
4836-13-9

N4-benzoyl-2'-deoxycytidine

Conditions
ConditionsYield
Stage #1: 2'-Deoxycytidine With pyridine; chloro-trimethyl-silane
Stage #2: benzoyl chloride With pyridine
Stage #3: ammonium hydroxide
96%
2-Methylpropionic anhydride
97-72-3

2-Methylpropionic anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-isobutyryll-2'-deoxycytidine
110522-75-3

N4-isobutyryll-2'-deoxycytidine

Conditions
ConditionsYield
In N,N-dimethyl-formamide95%
71%
tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

2'-deoxy-3',5'-bis-O-(tert-butyldimethylsilyl)cytidine
51549-29-2

2'-deoxy-3',5'-bis-O-(tert-butyldimethylsilyl)cytidine

Conditions
ConditionsYield
With pyridine at 20℃; for 48h;95%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 14h;95%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 10h; Inert atmosphere;88%
N2-(2-oxoethyl)guanine

N2-(2-oxoethyl)guanine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N2-(2-oxoethyl)deoxyguanosine

N2-(2-oxoethyl)deoxyguanosine

Conditions
ConditionsYield
With trans-N-deoxyribosylase from Lactobacillus helveticus In water at 37℃; for 15h; deoxyribosylation; Enzymatic reaction;95%
2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

4,4',4''-trimethoxytrityl chloride
49757-42-8

4,4',4''-trimethoxytrityl chloride

N4-(4,4',4
845306-87-8

N4-(4,4',4"-trimethoxytrityl)-2'-deoxycytidine

Conditions
ConditionsYield
With chloro-trimethyl-silane In pyridine at 20℃; for 16h;95%
Stage #1: 2'-Deoxycytidine With pyridine; chloro-trimethyl-silane at 20℃; for 2h;
Stage #2: 4,4',4''-trimethoxytrityl chloride With pyridine at 20℃; for 16h;
95%
Stage #1: 2'-Deoxycytidine With pyridine; chloro-trimethyl-silane at 20℃; for 2h;
Stage #2: 4,4',4''-trimethoxytrityl chloride With pyridine at 20℃; for 16h;
Stage #3: With ammonia In water
benzoyl chloride
98-88-4

benzoyl chloride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

C16H18N2O6

C16H18N2O6

Conditions
ConditionsYield
With pyridine; chloro-trimethyl-silane at 0℃; Inert atmosphere;95%
butanoic acid anhydride
106-31-0

butanoic acid anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Butyric acid (2R,3S,5R)-5-(4-butyrylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester
145355-76-6

Butyric acid (2R,3S,5R)-5-(4-butyrylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester

Conditions
ConditionsYield
In tetrahydrofuran at 60℃; for 6h; Candida antarctica lipase (SP435);94%
2,2-dimethoxy-1-methylpyrrolidine
39650-82-3

2,2-dimethoxy-1-methylpyrrolidine

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

4-N-(N-methylpyrrolidin-2-ylidene)-2’-deoxycytidine
98533-08-5

4-N-(N-methylpyrrolidin-2-ylidene)-2’-deoxycytidine

Conditions
ConditionsYield
In methanol for 1h;94%
In methanol at 20℃; for 3h; Inert atmosphere;85%
N,N-diisopropylformamide dimethyl acetal
19449-28-6

N,N-diisopropylformamide dimethyl acetal

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-<(diisopropylamino)methylene>-2'-deoxycytidine

N4-<(diisopropylamino)methylene>-2'-deoxycytidine

Conditions
ConditionsYield
In N,N-dimethyl-formamide for 8h; Ambient temperature;93%
phenyl isocyanate
103-71-9

phenyl isocyanate

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

2'-deoxy-N4-[(phenylamino)carbonyl]cytidine
219582-35-1

2'-deoxy-N4-[(phenylamino)carbonyl]cytidine

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 0.5h;92%
1-(p-nitrophenylethoxycarbonyl)-benzotriazole
88091-66-1

1-(p-nitrophenylethoxycarbonyl)-benzotriazole

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

2'-deoxy-N4-{[2-(4-nitrophenyl)ethoxy]carbonyl}cytidine
88091-67-2

2'-deoxy-N4-{[2-(4-nitrophenyl)ethoxy]carbonyl}cytidine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 60℃; for 15h;91%
In N,N-dimethyl-formamide at 60℃;90%
tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

β-D-5'-O-tert-butyldimethylsilyl-2'-deoxycytidine
51549-27-0

β-D-5'-O-tert-butyldimethylsilyl-2'-deoxycytidine

Conditions
ConditionsYield
With 1H-imidazole In N,N-dimethyl-formamide at 20℃;91%
2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

5-bromo-2'-deoxycytidine
1022-79-3

5-bromo-2'-deoxycytidine

Conditions
ConditionsYield
With N-Bromosuccinimide; acetic acid at 20℃; for 0.333333h;90%
With 1-(2-methoxyethyl)-3-methylimidazolium trifluoroacetate; N-Bromosuccinimide at 25℃; for 0.5h;85%
With bromine In pyridine; tetrachloromethane at 22℃; for 12h;72%
n-hexanoic anhydride
2051-49-2

n-hexanoic anhydride

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

Hexanoic acid (2R,3S,5R)-5-(4-hexanoylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester
145355-77-7

Hexanoic acid (2R,3S,5R)-5-(4-hexanoylamino-2-oxo-2H-pyrimidin-1-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl ester

Conditions
ConditionsYield
In tetrahydrofuran at 60℃; for 12h; Candida antarctica lipase (SP435);90%
N,N-dibutylformamide dimethyl acetal
19449-30-0

N,N-dibutylformamide dimethyl acetal

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

4-N-((di-n-butylamino)methylene)-2'-deoxycytidine
98533-10-9

4-N-((di-n-butylamino)methylene)-2'-deoxycytidine

Conditions
ConditionsYield
In methanol for 2h;90%
pentafluorophenyl benzoate
1548-84-1

pentafluorophenyl benzoate

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-benzoyl-2'-deoxycytidine
4836-13-9

N4-benzoyl-2'-deoxycytidine

Conditions
ConditionsYield
In pyridine at 80℃; for 5h;90%
di-tert-butylsilyl bis(trifluoromethanesulfonate)
85272-31-7

di-tert-butylsilyl bis(trifluoromethanesulfonate)

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

3',5'-O-(Di-tert-butylsilanediyl)deoxycytidine
97219-08-4

3',5'-O-(Di-tert-butylsilanediyl)deoxycytidine

Conditions
ConditionsYield
90%
N,N-dimethyl-formamide dimethyl acetal
4637-24-5

N,N-dimethyl-formamide dimethyl acetal

2'-Deoxycytidine
951-77-9

2'-Deoxycytidine

N4-<(dimethylamino)methylene>-2'-deoxycytidine
17331-11-2

N4-<(dimethylamino)methylene>-2'-deoxycytidine

Conditions
ConditionsYield
In N,N-dimethyl-formamide for 8h; Ambient temperature;90%
In methanol Ambient temperature; Yield given;

951-77-9Relevant academic research and scientific papers

Reactivity and DNA Damage by Independently Generated 2′-Deoxycytidin-N4-yl Radical

Peng, Haihui,Jie, Jialong,Mortimer, Ifor P.,Ma, Zehan,Su, Hongmei,Greenberg, Marc M.

, p. 14738 - 14747 (2021/09/18)

Oxidative stress produces a variety of radicals in DNA, including pyrimidine nucleobase radicals. The nitrogen-centered DNA radical 2′-deoxycytidin-N4-yl radical (dC·) plays a role in DNA damage mediated by one electron oxidants, such as HOCl and ionizing radiation. However, the reactivity of dC· is not well understood. To reduce this knowledge gap, we photochemically generated dC· from a nitrophenyl oxime nucleoside and within chemically synthesized oligonucleotides from the same precursor. dC· formation is confirmed by transient UV-absorption spectroscopy in laser flash photolysis (LFP) experiments. LFP and duplex DNA cleavage experiments indicate that dC· oxidizes dG. Transient formation of the dG radical cation (dG+?) is observed in LFP experiments. Oxidation of the opposing dG in DNA results in hole transfer when the opposing dG is part of a dGGG sequence. The sequence dependence is attributed to a competition between rapid proton transfer from dG+?to the opposing dC anion formed and hole transfer. Enhanced hole transfer when less acidicO6-methyl-2′-deoxyguanosine is opposite dC· supports this proposal. dC· produces tandem lesions in sequences containing thymidine at the 5′-position by abstracting a hydrogen atom from the thymine methyl group. The corresponding thymidine peroxyl radical completes tandem lesion formation by reacting with the 5′-adjacent nucleotide. As dC· is reduced to dC, its role in the process is traceless and is only detectable because of the ability to independently generate it from a stable precursor. These experiments reveal that dC· oxidizes neighboring nucleotides, resulting in deleterious tandem lesions and hole transfer in appropriate sequences.

Solid-phase synthesis and structural characterisation of phosphoroselenolate-modified DNA: A backbone analogue which does not impose conformational bias and facilitates SAD X-ray crystallography

Conlon, Patrick F.,Eguaogie, Olga,Wilson, Jordan J.,Sweet, Jamie S. T.,Steinhoegl, Julian,Englert, Klaudia,Hancox, Oliver G. A.,Law, Christopher J.,Allman, Sarah A.,Tucker, James H. R.,Hall, James P.,Vyle, Joseph S.

, p. 10948 - 10957 (2019/12/23)

Oligodeoxynucleotides incorporating internucleotide phosphoroselenolate linkages have been prepared under solid-phase synthesis conditions using dimer phosphoramidites. These dimers were constructed following the high yielding Michaelis-Arbuzov (M-A) reaction of nucleoside H-phosphonate derivatives with 5′-deoxythymidine-5′-selenocyanate and subsequent phosphitylation. Efficient coupling of the dimer phosphoramidites to solid-supported substrates was observed under both manual and automated conditions and required only minor modifications to the standard DNA synthesis cycle. In a further demonstration of the utility of M-A chemistry, the support-bound selenonucleoside was reacted with an H-phosphonate and then chain extended using phosphoramidite chemistry. Following initial unmasking of methyl-protected phosphoroselenolate diesters, pure oligodeoxynucleotides were isolated using standard deprotection and purification procedures and subsequently characterised by mass spectrometry and circular dichroism. The CD spectra of both modified and native duplexes derived from self-complementary sequences with A-form, B-form or mixed conformational preferences were essentially superimposable. These sequences were also used to study the effect of the modification upon duplex stability which showed context-dependent destabilisation (-0.4 to-3.1 °C per phosphoroselenolate) when introduced at the 5′-Termini of A-form or mixed duplexes or at juxtaposed central loci within a B-form duplex (-1.0 °C per modification). As found with other nucleic acids incorporating selenium, expeditious crystallisation of a modified decanucleotide A-form duplex was observed and the structure solved to a resolution of 1.45 ?. The DNA structure adjacent to the modification was not significantly perturbed. The phosphoroselenolate linkage was found to impart resistance to nuclease activity.

Identification of Flavin Mononucleotide as a Cell-Active Artificial N6-Methyladenosine RNA Demethylase

Xie, Li-Jun,Yang, Xiao-Ti,Wang, Rui-Li,Cheng, Hou-Ping,Li, Zhi-Yan,Liu, Li,Mao, Lanqun,Wang, Ming,Cheng, Liang

supporting information, p. 5028 - 5032 (2019/03/17)

N6-Methyladenosine (m6A) represents a common and highly dynamic modification in eukaryotic RNA that affects various cellular pathways. Natural dioxygenases such as FTO and ALKBH5 are enzymes that demethylate m6A residues in mRNA. Herein, the first identification of a small-molecule modulator that functions as an artificial m6A demethylase is reported. Flavin mononucleotide (FMN), the metabolite produced by riboflavin kinase, mediates substantial photochemical demethylation of m6A residues of RNA in live cells. This study provides a new perspective to the understanding of demethylation of m6A residues in mRNA and sheds light on the development of powerful small molecules as RNA demethylases and new probes for use in RNA biology.

Dehalogenation of Halogenated Nucleobases and Nucleosides by Organoselenium Compounds

Mondal, Santanu,Mugesh, Govindasamy

, p. 1773 - 1780 (2019/01/10)

Halogenated nucleosides, such as 5-iodo-2′-deoxyuridine and 5-iodo-2′-deoxycytidine, are incorporated into the DNA of replicating cells to facilitate DNA single-strand breaks and intra- or interstrand crosslinks upon UV irradiation. In this work, it is shown that the naphthyl-based organoselenium compounds can mediate the dehalogenation of halogenated pyrimidine-based nucleosides, such as 5-X-2′-deoxyuridine and 5-X-2′-deoxycytidine (X=Br or I). The rate of deiodination was found to be significantly higher than that of the debromination for both nucleosides. Furthermore, the deiodination of iodo-cytidines was found to be faster than that of iodo-uridines. The initial rates of the deiodinations of 5-iodocytosine and 5-iodouracil indicated that the nature of the sugar moiety influences the kinetics of the deiodination. For both the nucleobases and nucleosides, the deiodination and debromination reactions follow a halogen-bond-mediated and addition/elimination pathway, respectively.

Hydrogen peroxide-Triggered gene silencing in mammalian cells through boronated antisense oligonucleotides

Mori, Shohei,Morihiro, Kunihiko,Okuda, Takumi,Kasahara, Yuuya,Obika, Satoshi

, p. 1112 - 1118 (2018/02/09)

Hydrogen peroxide (H2O2) is a reactive oxygen species (ROS) involved in various diseases, including neurodegeneration, diabetes, and cancer. Here, we introduce a new approach to use H2O2 to modulate specific gene expression in mammalian cells. H2O2-responsive nucleoside analogues, in which the Watson-Crick faces of the nucleobases are caged by arylboronate moieties, were synthesized. One of these analogues, boronated thymidine (dTB), was incorporated into oligodeoxynucleotides (ODNs) using an automated DNA synthesizer. The hybridization ability of this boronated ODN to complementary RNA was clearly switched in the off-To-on direction upon H2O2 addition. Furthermore, we demonstrated H2O2-Triggered gene silencing in mammalian cells using antisense oligonucleotides (ASOs) modified with dTB. Our approach can be used for the regulation of any gene of interest by the sequence design of boronated ASOs and will contribute to the development of targeted disease therapeutics.

Novel nucleoside protective group and preparation thereof

-

Paragraph 0181-0187, (2018/03/24)

The invention relates to a novel nucleoside protective group and a preparation thereof. Concretely, the invention provides a compound with a structure shown in a formula 1, wherein R1 is selected from C1-C6 alkyl or C6-C14 aryl, preferably C1-C4 alkyl or phenyl, such as methyl, ethyl or phenyl; R2 is selected from C1-C6 alkyl or C6-C14 aryl substituted C1-C6 alkyl, preferably C1-C4 alkyl or phenyl substituted C1-C4 alkyl, such as methyl, ethyl, benzyl or phenethyl; X is halogen, and preferably chlorine. In the acidic condition, compared with traditional 4,4'-dismethoxytriphenylmethyl nucleoside protective group, deprotection of the compound is easier.

Copper-mediated arylsulfanylations and arylselanylations of pyrimidine or 7-deazapurine nucleosides and nucleotides

Botha, Filip,Slaví?ková, Michaela,Pohl, Radek,Hocek, Michal

supporting information, p. 10018 - 10022 (2016/11/06)

The syntheses of 5-arylsulfanyl- or 5-arylselanylpyrimidine and 7-arylsulfanyl- or 7-arylselanyl-7-deazapurine nucleosides and nucleotides were developed by the Cu-mediated sulfanylations or selanylations of the corresponding 5-iodopyrimidine or 7-iodo-7-

Mechanisms of allosteric activation and inhibition of the deoxyribonucleoside triphosphate triphosphohydrolase from Enterococcus faecalis

Vorontsov, Ivan I.,Wu, Ying,Delucia, Maria,Minasov, George,Mehrens, Jennifer,Shuvalova, Ludmilla,Anderson, Wayne F.,Ahn, Jinwoo

, p. 2815 - 2824 (2014/02/14)

EF1143 from Enterococcus faecalis, a life-threatening pathogen that is resistant to common antibiotics, is a homo-tetrameric deoxyribonucleoside triphosphate (dNTP) triphosphohydrolase (dNTPase), converting dNTPs into the deoxyribonucleosides and triphosphate. The dNTPase activity of EF1143 is regulated by canonical dNTPs, which simultaneously act as substrates and activity modulators. Previous crystal structures of apo-EF1143 and the protein bound to both dGTP and dATP suggested allosteric regulation of its enzymatic activity by dGTP binding at four identical allosteric sites. However, whether and how other canonical dNTPsregulatetheenzyme activity was not defined.Here, wepresent the crystal structure of EF1143 in complex with dGTP and dTTP. The new structure reveals that the tetrameric EF1143 contains four additional secondary allosteric sites adjacent to the previously identified dGTP-binding primary regulatory sites. Structural and enzyme kinetic studies indicate that dGTP binding to the first allosteric site, with nanomolar affinity, is a prerequisite for substrate docking and hydrolysis. Then, the presence of a particular dNTP in the second site either enhances or inhibits the dNTPase activity of EF1143. Our results provide the first mechanistic insight into dNTP-mediated regulation of dNTPase activity.

Mapping structurally defined guanine oxidation products along DNA duplexes: Influence of local sequence context and endogenous cytosine methylation

Ming, Xun,Matter, Brock,Song, Matthew,Veliath, Elizabeth,Shanley, Ryan,Jones, Roger,Tretyakova, Natalia

, p. 4223 - 4235 (2014/04/03)

DNA oxidation by reactive oxygen species is nonrandom, potentially leading to accumulation of nucleobase damage and mutations at specific sites within the genome. We now present the first quantitative data for sequence-dependent formation of structurally defined oxidative nucleobase adducts along p53 gene-derived DNA duplexes using a novel isotope labeling-based approach. Our results reveal that local nucleobase sequence context differentially alters the yields of 2,2,4-triamino-2H-oxal-5-one (Z) and 8-oxo-7,8-dihydro-2′- deoxyguanosine (OG) in double stranded DNA. While both lesions are overproduced within endogenously methylated MeCG dinucleotides and at 5′ Gs in runs of several guanines, the formation of Z (but not OG) is strongly preferred at solvent-exposed guanine nucleobases at duplex ends. Targeted oxidation of MeCG sequences may be caused by a lowered ionization potential of guanine bases paired with MeC and the preferential intercalation of riboflavin photosensitizer adjacent to MeC:G base pairs. Importantly, some of the most frequently oxidized positions coincide with the known p53 lung cancer mutational hotspots at codons 245 (GGC), 248 (CGG), and 158 (CGC) respectively, supporting a possible role of oxidative degradation of DNA in the initiation of lung cancer.

Deamination, oxidation, and C-C bond cleavage reactivity of 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxycytosine

Schiesser, Stefan,Pfaffeneder, Toni,Sadeghian, Keyarash,Hackner, Benjamin,Steigenberger, Barbara,Schroeder, Arne S.,Steinbacher, Jessica,Kashiwazaki, Gengo,Hoefner, Georg,Wanner, Klaus T.,Ochsenfeld, Christian,Carell, Thomas

, p. 14593 - 14599 (2013/10/22)

Three new cytosine derived DNA modifications, 5-hydroxymethyl-2′- deoxycytidine (hmdC), 5-formyl-2′-deoxycytidine (fdC) and 5-carboxy-2′-deoxycytidine (cadC) were recently discovered in mammalian DNA, particularly in stem cell DNA. Their function is currently not clear, but it is assumed that in stem cells they might be intermediates of an active demethylation process. This process may involve base excision repair, C-C bond cleaving reactions or deamination of hmdC to 5-hydroxymethyl-2′- deoxyuridine (hmdU). Here we report chemical studies that enlighten the chemical reactivity of the new cytosine nucleobases. We investigated their sensitivity toward oxidation and deamination and we studied the C-C bond cleaving reactivity of hmdC, fdC, and cadC in the absence and presence of thiols as biologically relevant (organo)catalysts. We show that hmdC is in comparison to mdC rapidly oxidized to fdC already in the presence of air. In contrast, deamination reactions were found to occur only to a minor extent. The C-C bond cleavage reactions require the presence of high concentration of thiols and are acid catalyzed. While hmdC dehydroxymethylates very slowly, fdC and especially cadC react considerably faster to dC. Thiols are active site residues in many DNA modifiying enzymes indicating that such enzymes could play a role in an alternative active DNA demethylation mechanism via deformylation of fdC or decarboxylation of cadC. Quantum-chemical calculations support the catalytic influence of a thiol on the C-C bond cleavage.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 951-77-9